The company said worldwide net revenues for the Q2 2025 were $15.423 billion, an increase of 6.6% on a reported basis and 6.5% on an operational basis. Diluted EPS was $0.52 on a GAAP basis and $2.97 on an adjusted basis.

1. 01

   The company said worldwide net revenues for the Q2 2025 were $15.423 billion, an increase of 6.6% on a reported basis and 6.5% on an operational basis. Diluted EPS was $0.52 on a GAAP basis and $2.97 on an adjusted basis.

2. 02

   AbbVie said immunology net revenues for the Q2 were $7.631 billion, up 9.5% on a reported basis. Skyrizi net revenues were $4.423 billion, Rinvoq $2.028 billion and Humira $1.180 billion. Neuroscience net revenues were $2.683 billion, up 24.2% on a reported basis.

3. 03

   The company said GAAP diluted EPS for Q2 was $0.52 and adjusted diluted EPS was $2.97, and that these results included an unfavorable impact of $0.42 per share from acquired IPR&D and milestones expense. Specified adjustments include a change in fair value of contingent consideration of $1.53 per share and intangible asset amortization of $0.89 per share.

4. 04

   The company said it is raising its 2025 full-year adjusted diluted EPS guidance to $11.88 - $12.08 from $11.67 - $11.87. The guidance includes an unfavorable impact of $0.55 per share from acquired IPR&D and milestones expense incurred year to date through Q2.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.